Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.